ACSR Funding Opportunities
MEET OUR YOUNG INVESTIGATOR PILOT AWARD AWARDEES!
The ACSR is committed to supporting the next generation of HIV researchers by offering a grant award program for early-stage investigators interested in conducting HIV-related research, especially for malignancies. The goal is to encourage novel and rigorous scientific research projects that utilize biospecimens and data in the ACSR inventory via a small grant funding mechanism and contribute toward greater understanding of HIV disease, biology, improved treatment, and discovery of a cure. See below to learn more about our YOUNG INVESTIGATOR PILOT AWARD (YIPA) opportunities as well as our past and current awardees. Click here to register for email updates about this and other HIV funding opportunities.
-
ACSR YOUNG INVESTIGATOR PILOT AWARD: FALL LOI CYCLE IS CLOSED! Please contact us for more information on upcoming cycles.
Other Funding Opportunities
Funding opportunities from non-ACSR sources
National Institutes of Health (NIH) Funding Opportunity Announcements
-
Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional): PAR-23-024. This funding opportunity announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas in HIV/AIDS research related to coinfections, comorbidities, and complications. Earliest Submission date: April 01, 2023
-
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed): RFA-CA-22-056. Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae. Expiration date: December 16, 2023.
-
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed): RFA-CA-22-057. Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae. Expiration date: December 16, 2023.
-
The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional): PAR-21-348. This funding opportunity announcement (FOA) focuses on the role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection. The goal is to increase our knowledge through mechanistic, epidemiological, or translational studies that examine how EBV promotes NHL or HD initiation, progression, and the resulting disease sequelae and to provide insights into mechanistic differences in the relationship between EBV infection and lymphomagenesis in HIV+ versus HIV- persons. Research project U01s funded through this PAR will form a cooperative group, the Epstein Barr Virus associated Lymphoma Consortium (EALC). Expiration date: December 16, 2023.
